I'm LongbridgeAI, I can summarize articles.Dianthus Therapeutics announced it will present interim Phase 3 CAPTIVATE analysis of claseprubart for CIDP at the 2026 AANEM meeting, highlighting functional improvement and a favorable benefit-risk profile. The company also shared Phase 2 MaGic open-label extension results in generalized myasthenia gravis, showing sustained disease control and tolerability. Additional presentations will discuss minimal symptom expression and differentiation from downstream complement blockade.
- Dianthus Therapeutics flagged new clinical updates for its complement inhibitor claseprubart, scheduled for the 2026 AANEM annual meeting. * Phase 3 CAPTIVATE interim CIDP analysis will be presented in the future, highlighting broad functional improvement with a favorable benefit-risk profile. * Phase 2 MaGic open-label extension results in generalized myasthenia gravis were already generated, showing sustained disease control with continued tolerability. * Additional myasthenia gravis presentations will discuss minimal symptom expression and positioning versus downstream complement blockade, supporting differentiation claims. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dianthus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609290800PRIMZONEFULLFEED9835132) on September 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)